Articles tagged with: Amgen
Amgen’s Plan for Denosumab (NASDAQ:AMGN)
On Thursday, Amgen, Inc. (NASDAQ:AMGN) have opened up about the new plans about how the company will actually handle the request for the new information asked by the Food and Drug Administration panel.
Amgen faces FDA delays (NASDAQ:AMGN)
On Monday morning Amgen Inc made an announcement that the Food and Drug Administration has issued them a Complete Response letter for the Biologic License Applications (BLA) for their new bone drug Denosumab (Prolia) for …
Amgen Facing Delays (NASDAQ:AMGN)
Amgen Inc is not really sure if they will have to wait or not but many of the biotech investors have speculated that Amgen’s Bone drug may have to face significant delays in the final …
